Safety and Immunogenicity Study of a Booster Dose of the Investigational CV0501 mRNA COVID-19 Vaccine in Adults at Least 18 Years Old

Trial Identifier: 218595
Sponsor: GlaxoSmithKline
Start Date: August 2022
Primary Completion Date: August 2023
Study Completion Date: August 2023
Condition: COVID-19 Immunisation

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
Australia, NSW Brookvale, NSW, Australia, 2100
Australia, NSW Merewether, NSW, Australia, 2291
Australia, NSW Sydney, NSW, Australia, 2010
Australia, NSW Wollongong, NSW, Australia, 2500
Philippines Cavite, Philippines, 4114
Philippines Iloilo City, Philippines, 5000
United States, CA Sacramento, CA, United States, 95864
United States, FL Hollywood, FL, United States, 33024
United States, FL Melbourne, FL, United States, 32934
United States, GA Savannah, GA, United States, 31406
United States, IL Peoria, IL, United States, 61614-4896
United States, LA Metairie, LA, United States, 70006-5322
United States, MD Rockville, MD, United States, 20854
United States, NE Omaha, NE, United States, 68134
United States, NY Binghamton, NY, United States, 13760
United States, OH Cincinnati, OH, United States, 45212
United States, VA Norfolk, VA, United States, 68701